Lv2
110 积分 2026-07-28 加入
Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group
14天前
已完结
Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer
14天前
已完结
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
15天前
已完结
The immunology of human breast cancer
24天前
已完结
A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab in hormone receptor (HR)-positive, HER2-positive metastatic breast cancer (ASPIRE)
28天前
已完结
First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial
1个月前
已完结
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival
1个月前
已完结
Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus
1个月前
已完结
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial
1个月前
已完结
Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1
1个月前
已完结
皖公网安备34019202002308
